Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan

Chi Yi Chen, Chung Feng Huang, Pin Nan Cheng, Kuo Chih Tseng, Ching Chu Lo, Hsing Tao Kuo, Yi Hsiang Huang, Chi Ming Tai, Cheng Yuan Peng, Ming Jong Bair, Chien Hung Chen, Ming Lun Yeh, Chih Lang Lin, Chun Yen Lin, Pei Lun Lee, Lee Won Chong, Chao Hung Hung, Jee Fu Huang, Chi Chieh Yang, Jui Ting HuChih Wen Lin, Chun Ting Chen, Chia Chi Wang, Wei Wen Su, Tsai Yuan Hsieh, Chih Lin Lin, Wei Lun Tsai, Tzong Hsi Lee, Guei Ying Chen, Szu Jen Wang, Chun Chao Chang, Lein Ray Mo, Sheng Shun Yang, Wen Chih Wu, Chia Sheng Huang, Chou Kwok Hsiung, Chien Neng Kao, Pei Chien Tsai, Chen Hua Liu, Mei Hsuan Lee, Chun Jen Liu, Chia Yen Dai, Jia Horng Kao, Wan Long Chuang, Han Chieh Lin, Ming Lung Yu

研究成果: 雜誌貢獻文章同行評審

4 引文 斯高帕斯(Scopus)

摘要

Background/aims: Direct-acting antivirals (DAAs) are highly effective in treating chronic hepatitis C virus (HCV)-infected patients. The real-world treatment outcome in Taiwanese patients on a nationwide basis is elusive. Methods: The Taiwan HCV Registry (TACR) programme is a nationwide registry platform including 48 study sites, which is organized and supervised by the Taiwan Association for the Study of the Liver. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA 12 weeks after end-of-treatment). Results: A total of 13 951 registered patients with SVR12 data available were analysed (mean age, 63.0 years; female, 55.9%; HCV genotype-1 [GT1], 57.9%; cirrhosis, 38.4%; preexisting hepatocellular carcinoma [HCC], 10.6%; and hepatitis B virus coinfection, 7.7%). The overall SVR12 rate was 98.3%, with 98.7%, 98.0%, 98.4% and 97.4% in treatment-naïve noncirrhotic, treatment-naïve cirrhotic, treatment-experienced noncirrhotic and treatment-experienced cirrhotic patients, respectively. The SVR12 rate was > 95% across all subgroups except treatment-experienced cirrhotic patients who received sofosbuvir/ribavirin (88.7%), treatment-naïve noncirrhotic patients (94.8%) and treatment-experienced cirrhotic (94.8%) patients who received daclatasvir/asunaprevir. The most important factor associated with treatment failure was DAA adherence < 60% (adjusted odds ratio [aOR]/95% confidence interval [CI]: 117.1/52.4-261.3, P <.001), followed by GT3/GT2 (aOR/CI: 5.78/2.25-14.9, P =.0003 and aOR/CI: 1.55/1.05-2.29, P =.03, compared with GT1), active hepatocellular carcinoma (aOR/CI: 4.29/2.57-7.16, P <.001), the use of sofosbuvir/ribavirin (aOR/CI: 2.51/1.67-3.77, P <.001) and daclatasvir/asunaprevir (aOR/CI: 3.29/1.94-5.58, P <.001), decompensated liver cirrhosis (aOR/CI: 2.50/1.20-5.22, P =.02) and high HCV viral loads (aOR/CI: 2.16/1.57-2.97, P <.001). Conclusions: DAAs are highly effective in treating Taiwanese HCV patients in the real-world setting. Maintaining DAA adherence and selecting highly efficacious regimens are keys to ensure treatment success.
原文英語
頁(從 - 到)1265-1277
頁數13
期刊Liver International
41
發行號6
DOIs
出版狀態接受/付印 - 2021

ASJC Scopus subject areas

  • 肝病

指紋

深入研究「Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan」主題。共同形成了獨特的指紋。

引用此